Moderna Stock: Buy the Dip?

1 min read

Moderna (NASDAQ: MRNA) stock is down 9% on Monday after Bank of America analyst Geoff Meacham downgraded his opinion on the stock from neutral to underperform and kept his $150 target on the shares. Moderna, which traded hands at $185 on Friday, opened at $173 and dropped down to $154 in early trading.

The biotech stock skyrocketed in 2020 because of the COVID-19 pandemic, running up from $19 a share to $111. Moderna’s messenger RNA (mRNA) platform allows it to find vaccines quickly and get them into clinical trials before its rivals. Meanwhile, Pfizer signed a collaboration agreement with another biotech, BioNTech, another mRNA specialist, to develop its COVID-19 vaccine. Moderna and Pfizer were neck-and-neck all year in the race to get COVID-19 vaccines to the public. The Food and Drug Administration (FDA) granted emergency use authorization to both companies in December.

image source: Getty Images

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

How Safe Is B&G Foods and Its Dividend?

Next Story

Why Churchill Capital Stock Gained Again Today

Latest from Blog